Biotech & Biopharma
生物技术与生物医药
China's biotech sector has exploded, with hundreds of innovative biotech companies developing novel drugs, cell therapies, and gene editing technologies. Biotech parks in Suzhou, Shanghai, and Beijing rival Boston and San Francisco.
Hubs
5
cities with this sector
Total Output
¥333B
combined industry output
Companies
2,200
across all hubs
Employment
358K
workers in sector
Key Statistics
Biotech companies
6,000+
2024
IND applications (global)
#2 worldwide
2024
Biopharma market size
¥520B
2023
Global Context
Chinese biotechs filed the second-most global IND applications in 2024. The sector faces scrutiny from the US BIOSECURE Act.
Hub Rankings
Shanghai上海
Tier 1rapidInnovative drug development, CAR-T therapy, antibody engineering
Suzhou苏州
Tier 2rapidInnovative drugs (PD-1, ADC), CRO/CDMO, gene therapy
Wuhan武汉
Tier 2steadyVaccines, biological products, CRO/CDMO services
Guangzhou广州
Tier 2rapidRegenerative medicine, cell therapy, biosimilars
Zhuhai珠海
Tier 3emergingBiomedical devices, traditional medicine modernization, biosimilars
Policy Drivers
- 14th Five-Year Bioeconomy Plan
- MAH (Marketing Authorization Holder) reform
- Biotech park incentives
Key Companies
WuXi AppTec
药明康德
World's leading pharmaceutical and biotech R&D outsourcing platform, providing end-to-end drug discovery and development services.
Shanghai, Shanghai →Innovent Biologics
信达生物
Leading innovative biopharmaceutical company, known for PD-1 antibody and partnership with Eli Lilly.
Suzhou, Jiangsu →BaseCare Medical
贝康医疗
Pioneer in reproductive genetics and molecular diagnostics, offering next-generation sequencing-based preimplantation genetic testing.
Suzhou, Jiangsu →GenScript ProBio (Suzhou)
金斯瑞蓬勃(苏州)
Global CDMO for cell and gene therapy, with major production and development facilities in BioBay.
Suzhou, Jiangsu →BGI Genomics (South China)
BGI华大基因(华南)
Branch of the world's largest genomics organization, operating sequencing platforms and clinical testing services in the Greater Bay Area.
Guangzhou, Guangdong →